DMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15mg products from USWM, LLC
Adamis Pharmaceuticals Corporation announced that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc., a division...
Adamis Pharmaceuticals Corporation announced that the FDA has accepted for review the Company�s supplemental New Drug Application (�sNDA�) for its...
Adamis Pharmaceuticals Corporation announced it is reacquiring from Sandoz Inc. the rights to its Symjepi(epinephrine) Injection 0.3mg, Symjepi (epinephrine) Injection 0.15mg products currently marketed and available in the United States.
Adamis Pharmaceuticals Corporation announced that the FDA has approved Adamis� lower dose version (0.15mg) of Symjepi for the emergency treatment...
Adamis Pharmaceuticals Corporation announced that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty to...
FDA approves Symjepi (epinephrine Injection pre-filled single dose syringe) for the emergency treatment of allergic reactions (Type I) including anaphylaxis.
Adamis Pharmaceuticals Corporation announced that the FDA has accepted for review the company’s New Drug Application (“NDA”) for its higher...